5-methoxy-N,N-dimethyltryptamine
- Generic Name
- 5-methoxy-N,N-dimethyltryptamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18N2O
- CAS Number
- 1019-45-0
- Unique Ingredient Identifier
- X0MKX3GWU9
- Background
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a tryptamine with psychedelic properties. It is found in a wide variety of plant species, and a single psychoactive toad species, the Colorado River toad. This drug, as well as dimethyltryptamine and bufotenin, have been registered to be used in South America in religious and spiritual rituals.
- Associated Conditions
- -
- Associated Therapies
- -
GH Research reports deeper losses as DMT clinical trial costs mount
GH Research PLC reported a $12.1 million Q3 net loss, with rising R&D and G&A costs, but maintains $193.8 million in cash. It completed enrollment for its phase 2b trial of GH001 for treatment-resistant depression, with top-line data expected in Q4 2024 or Q1 2025. The FDA has placed its GH001 IND on clinical hold due to insufficient risk assessment, and it plans to end its bipolar II disorder trial in Q4 2024 due to recruitment issues.
DEA Calls To Increase Production of Psychedelics For Clinical Research
The DEA proposed increasing psilocybin, psilocin, and ibogaine production quotas by 50% for 2025, signaling support for psychedelic research. This follows a growing interest in studying these compounds for mental health treatments, despite their Schedule 1 status. The VA is also increasingly involved in psychedelic-assisted therapy research for veterans.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath